Phase I Dose-Escalation Results for Marizomib in Newly Diagnosed Glioblastoma
Daniela A. Bota, MD, medical director of Neuro-Oncology at University of California Irvine, discusses the findings from a dose-escalation trial of marizomib.
Daniela A. Bota, MD, medical director of Neuro-Oncology at University of California Irvine, discusses the findings from a dose-escalation trial of marizomib.
According to the results, marizomib is a well-tolerated drug amongst patients with newly diagnosed glioblastoma. The recommended dose identified in this trial was 0.8 mg/m2. The drug will be administered at days 1, 8, and 15 in a 28-day cycle, Bota explains.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
